![]() Following the transaction, the director now owns 176,050 shares in the company, valued at approximately $8,830,668. The shares were sold at an average price of $50.16, for a total value of $501,600.00. Albers sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 25th. In other Blueprint Medicines news, Director Jeffrey W. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Following the transaction, the insider now owns 38,117 shares in the company, valued at approximately $1,984,371.02. The shares were sold at an average price of $52.06, for a total value of $120,102.42. Carter sold 2,307 shares of the company’s stock in a transaction that occurred on Monday, June 5th. In other Blueprint Medicines news, insider Percy H. acquired a new stake in shares of Blueprint Medicines in the 1st quarter worth approximately $219,000. NewEdge Wealth LLC acquired a new stake in shares of Blueprint Medicines in the 1st quarter worth approximately $247,000. now owns 633,408 shares of the biotechnology company’s stock valued at $28,497,000 after purchasing an additional 32,126 shares during the period. boosted its stake in Blueprint Medicines by 5.3% during the 1st quarter. now owns 90,526 shares of the biotechnology company’s stock valued at $4,073,000 after purchasing an additional 28,340 shares during the period. boosted its stake in Blueprint Medicines by 45.6% during the 1st quarter. Bank of New York Mellon Corp now owns 263,557 shares of the biotechnology company’s stock valued at $11,857,000 after purchasing an additional 1,021 shares during the period. Bank of New York Mellon Corp boosted its stake in Blueprint Medicines by 0.4% during the 1st quarter. Tower Research Capital LLC TRC’s holdings in Blueprint Medicines were worth $102,000 at the end of the most recent quarter.Ī number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. The firm owned 2,273 shares of the biotechnology company’s stock after purchasing an additional 1,254 shares during the period. ![]() ( NASDAQ:BPMC – Free Report) by 123.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. Tower Research Capital LLC TRC raised its position in shares of Blueprint Medicines Co.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |